What impact will genetic changes have on new medicines currently in development?

It’s the timeless story: Teva wants Mylan, Mylan wants Perrigo, and Perrigo wants none of it

By eliminating protein A, researchers aim to deliver continuous processing at a fraction of the cost of conventional techniques.

We speak to Professor Begoña Calvo to find out more about her research into pharmaco vigilance for biosimilars.

The first US biosimilar has been pocketed and the game is on. We bring six experts to the table to discuss the impact on industry dynamics.

$100 million pledged to kick start investment in new research

FDA scolds company for revealing interim trial results

Just how prevalent is pharmacogenomic information on European drug labels?

New technology interprets slang and banter to find out what people really think

An antimalarial medicine-making project wins the inaugural Humanity in Science Award.